{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:59Z","timestamp":1792114139321,"version":"4.4.0"},"reference-count":157,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Aside from their key protective roles in hemostasis and innate immunity, platelets are now recognized as having multifaceted, adverse roles in the pathogenesis, progression and outcome of many types of human malignancy. The most consistent and compelling evidence in this context has been derived from the notable association of elevated circulating platelet counts with the onset and prognosis of various human malignancies, particularly lung cancer, which represents the primary focus of the current review. Key topics include an overview of the association of lung cancer with the circulating platelet count, as well as the mechanisms of platelet-mediated, pro-tumorigenic immunosuppression, particularly the role of transforming growth factor beta 1. These issues are followed by a discussion regarding the pro-tumorigenic role of platelet-derived microparticles (PMPs), the most abundant type of microparticles (MPs) in human blood. In this context, the presence of increased levels of PMPs in the blood of lung cancer patients has been associated with tumor growth, invasion, angiogenesis and metastasis, which correlate with disease progression and decreased survival times. The final section of the review addresses, firstly, the role of cancer-related platelet activation and thrombosis in the pathogenesis of secondary cardiovascular disorders and the associated mortality, particularly in lung cancer, which is second only to disease progression; secondly, the review addresses the potential role of antiplatelet agents in the adjunctive therapy of cancer.<\/jats:p>","DOI":"10.3390\/ijms241511927","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:45:02Z","timestamp":1690332302000},"page":"11927","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-6452","authenticated-orcid":false,"given":"Ronald","family":"Anderson","sequence":"first","affiliation":[{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-3653","authenticated-orcid":false,"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"},{"name":"The Medical Oncology Centre of Rosebank, Johannesburg 2196, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-4472","authenticated-orcid":false,"given":"Helen C.","family":"Steel","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7359-5952","authenticated-orcid":false,"given":"Annette J.","family":"Theron","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.3399\/bjgp20X710957","article-title":"Cancer incidence following a high-normal platelet count: Cohort study using electronic healthcare records from English primary care","volume":"70","author":"Mounce","year":"2020","journal-title":"Br. J. Gen. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2141633","DOI":"10.1001\/jamanetworkopen.2021.41633","article-title":"Analysis of platelet count and new cancer diagnosis over a 10-year period","volume":"5","author":"Giannakeas","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Giannakeas, V., Kotsopoulos, J., Brooks, J.D., Cheung, M.C., Rosella, L., Lipscombe, L., Akbari, M.R., Austin, P.C., and Narod, S.A. (2022). Platelet count and survival after cancer. Cancers, 14.","DOI":"10.3390\/cancers14030549"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01307186","article-title":"Platelets and cancer metastasis: A causal relationship?","volume":"11","author":"Honn","year":"1992","journal-title":"Cancer Metastasis Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(02)00789-1","article-title":"Platelets and cancer","volume":"3","author":"Nash","year":"2002","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1055\/s-0038-1647347","article-title":"The platelet count in carcinoma of the lung and colon","volume":"64","author":"Costantini","year":"1990","journal-title":"Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3892\/etm.2013.1003","article-title":"Platelet count predicts prognosis in operable non-small cell lung cancer","volume":"5","author":"Yu","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/09537104.2014.888547","article-title":"Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients","volume":"26","author":"Ji","year":"2015","journal-title":"Platelets"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1055-9965.EPI-18-0356","article-title":"Elevated platelet count appears to be causally associated with increased risk of lung cancer: A mendelian randomization analysis","volume":"28","author":"Zhu","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature10659","article-title":"New gene functions in megakaryopoiesis and platelet formation","volume":"480","author":"Gieger","year":"2011","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ng.3892","article-title":"Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes","volume":"49","author":"McKay","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.21037\/tcr-20-3287","article-title":"The association between thrombocytosis and subtype of lung cancer: A systematic review and meta-analysis","volume":"10","author":"Barlow","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Zhong, H., Ye, L., Li, Q., Fang, S., Gu, W., and Qian, Y. (2020). Prognostic value of pretreatment platelet counts in lung cancer: A systematic review and meta-analysis. BMC Pulm. Med., 20.","DOI":"10.1186\/s12890-020-1139-5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1038\/s41598-019-41289-9","article-title":"Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion","volume":"9","author":"Lim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12032-009-9217-9","article-title":"Platelet count: Association with prognosis in lung cancer","volume":"27","year":"2010","journal-title":"Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.7150\/jca.20866","article-title":"Prognostic significance of host-related biomarkers for survival in patients with advanced non-small cell lung cancer","volume":"8","author":"Lee","year":"2017","journal-title":"J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.annepidem.2005.06.052","article-title":"Platelet counts differ by sex, ethnicity, and age in the United States","volume":"16","author":"Segal","year":"2006","journal-title":"Ann. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature21706","article-title":"The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors","volume":"544","author":"Caudrillier","year":"2017","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1152\/physiol.00017.2019","article-title":"Platelet biogenesis in the lung circulation","volume":"34","author":"Looney","year":"2019","journal-title":"Physiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.celrep.2016.10.031","article-title":"PF4 promotes platelet production and lung cancer growth","volume":"17","author":"Pucci","year":"2016","journal-title":"Cell Rep."},{"key":"ref_21","first-page":"21","article-title":"Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer","volume":"1775","author":"Pardali","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0189-8","article-title":"TGF-\u03b2 downregulation-induced cancer cell death is finely regulated by the SAPK signaling cascade","volume":"50","author":"Han","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eaai7911","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-020-17811-3","article-title":"Selective inhibition of TGF-\u03b21 produced by GARP-expressing Tregs overcomes resistance to PD-1\/PD-L1 blockade in cancer","volume":"11","author":"Bertrand","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-018-0570-z","article-title":"Immunoregulatory functions and the therapeutic implications of GARP-TGF-\u03b2 in inflammation and cancer","volume":"11","author":"Metelli","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4355386","DOI":"10.1155\/2022\/4355386","article-title":"Tumor-associated regulatory T cells in non-small-cell lung cancer: Current advances and future perspectives","volume":"2022","author":"Liang","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"684098","DOI":"10.3389\/fonc.2021.684098","article-title":"Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung cancer","volume":"11","author":"Principe","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Li, J., Shen, C., Wang, X., Lai, Y., Zhou, K., Li, P., Liu, L., and Che, G. (2019). Prognostic value of TGF-\u03b2 in lung cancer: Systematic review and meta-analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5917-5"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1084\/jem.20012076","article-title":"Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation","volume":"195","author":"Gorelik","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3389\/fimmu.2019.02689","article-title":"Impairment of NKG2D-mediated tumor immunity by TGF-\u03b2","volume":"10","author":"Lazarova","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eabo4577","DOI":"10.1126\/sciadv.abo4577","article-title":"SMAD4, activated by the TCR-triggered MEK\/ERK signaling pathway, critically regulates CD8+ T cell cytotoxic function","volume":"8","author":"Liu","year":"2022","journal-title":"Sci Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1066336","DOI":"10.3389\/fimmu.2022.1066336","article-title":"The antitumor activity of human V\u03b39V\u03b42 T cells is impaired by TGF-\u03b2 through significant phenotype, transcriptomic and metabolic changes","volume":"13","author":"Rafia","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25\u2212 naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.immuni.2010.04.012","article-title":"Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development","volume":"32","author":"Ouyang","year":"2010","journal-title":"Immunity"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-019-1967-3","article-title":"Blockade of TGF-\u03b2 signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25\u2212Foxp3+ T cells","volume":"17","author":"Polanczyk","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e94075","DOI":"10.1172\/jci.insight.94075","article-title":"Human lung tumor FOXP3+ Tregs upregulate four \u201cTreg-locking\u201d transcription factors","volume":"2","author":"Akimova","year":"2017","journal-title":"JCI Insight"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Al-Mterin, M.A., Murshed, K., and Elkord, E. (2022). Correlations between circulating and tumor-infiltrating CD4+ Treg subsets with immune checkpoints in colorectal cancer patients with early and advanced stages. Vaccines, 10.","DOI":"10.3390\/vaccines10091471"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2006-12-064527","article-title":"Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression","volume":"110","author":"Borsellino","year":"2007","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/cei.12354","article-title":"Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells","volume":"177","author":"Schuler","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41590-018-0280-2","article-title":"Regulatory T cells mediate specific suppression by depleting peptide-MHC class II from dendritic cells","volume":"20","author":"Akkaya","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3389\/fimmu.2017.01461","article-title":"The role of transforming growth factor beta-1 in the progression of HIV\/AIDS and development of non-AIDS-defining fibrotic disorders","volume":"8","author":"Theron","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1042\/CS20201236","article-title":"Therapeutic targeting of TGF-\u03b2 in cancer: Hacking a master switch of immune suppression","volume":"135","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_46","first-page":"1860","article-title":"Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines","volume":"63","author":"Kobie","year":"2003","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci. Signal."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E10915","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"52294","DOI":"10.18632\/oncotarget.10561","article-title":"TGF-\u03b2 induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.3389\/fimmu.2018.02456","article-title":"Understanding the multifaceted role of neutrophils in cancer and autoimmune diseases","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e005837","DOI":"10.1136\/jitc-2022-005837","article-title":"Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma","volume":"11","author":"Liu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"eabq6221","DOI":"10.1126\/scitranslmed.abq6221","article-title":"Neutralization of NET-associated human ARG1 enhances cancer immunotherapy","volume":"15","author":"Barouni","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.7314\/APJCP.2014.15.18.7825","article-title":"Experimental study on inhibition effects of the XAF1 gene against lung cancer cell proliferation","volume":"15","author":"Yang","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_54","first-page":"4663","article-title":"Combined effects of XAF1 and TRAIL on the apoptosis of lung adenocarcinoma cells","volume":"17","author":"Zhang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_55","first-page":"2117","article-title":"TGF-\u03b21 protects colon tumor cells from apoptosis through XAF1 suppression","volume":"54","author":"Moon","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10597","DOI":"10.1038\/s41598-020-67325-7","article-title":"TGF-\u03b2 induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","article-title":"Role of platelets and platelet receptors in cancer metastasis","volume":"11","author":"Schlesinger","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"600616","DOI":"10.3389\/fmedt.2020.600616","article-title":"In vitro studies of transendothelial migration for biological and drug discovery","volume":"2","author":"Salminen","year":"2020","journal-title":"Front. Med. Technol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1172\/JCI94624","article-title":"Fibroblast-specific inhibition of TGF-\u03b21 signaling attenuates lung and tumor fibrosis","volume":"127","author":"Wei","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_61","first-page":"e125326","article-title":"PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis","volume":"4","author":"Geng","year":"2019","journal-title":"JCI Insight"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1096\/fj.201902354R","article-title":"Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD-L1 into extracellular vesicles","volume":"34","author":"Kang","year":"2020","journal-title":"FASEB J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9466","DOI":"10.1038\/s41598-018-27710-9","article-title":"CXCL4\/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration","volume":"8","author":"Fox","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/cam4.455","article-title":"Circulating TGF-\u03b21 and VEGF and risk of cancer among liver transplant recipients","volume":"4","author":"Engels","year":"2015","journal-title":"Cancer Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","article-title":"RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics","volume":"28","author":"Best","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1158\/0008-5472.CAN-18-0887","article-title":"Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring","volume":"78","author":"Best","year":"2018","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1182\/blood.2019003976","article-title":"Lessons to learn from tumor-educated platelets","volume":"137","author":"Roweth","year":"2021","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/0008-5472.CAN-19-1181","article-title":"The interaction of platelets with colorectal cancer cells inhibits tumor growth but promotes metastasis","volume":"80","author":"Plantureux","year":"2020","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e23791","DOI":"10.1002\/jcla.23791","article-title":"Identification of seven tumor-educated platelets RNAs for cancer diagnosis","volume":"35","author":"Ge","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_70","first-page":"e19189","article-title":"Tumor-educated platelets: A review of current and potential applications in solid tumors","volume":"13","author":"Varkey","year":"2021","journal-title":"Cureus"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-0040-1708827","article-title":"A champion of host defense: A generic large-scale cause for platelet dysfunction and depletion in infection","volume":"46","author":"Page","year":"2020","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"107692","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"292376","DOI":"10.1155\/2014\/292376","article-title":"The inflammatory chemokine CCL5 and cancer progression","volume":"2014","author":"Aldinucci","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1055\/s-0030-1267043","article-title":"Microparticles in cancer","volume":"36","author":"Rak","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4137\/BIC.S30347","article-title":"Microparticles as biomarkers of blood coagulation in cancer","volume":"7","author":"Nomura","year":"2015","journal-title":"Biomark. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood.2019004119","article-title":"Platelets and extracellular vesicles and their cross talk with cancer","volume":"137","author":"Lazar","year":"2021","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.34172\/apb.2021.005","article-title":"Platelet microparticle controversial role in cancer","volume":"11","author":"Nazari","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/jid.2013.288","article-title":"Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma","volume":"134","author":"Laresche","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.31557\/APJCP.2021.22.5.1573","article-title":"Platelet-derived procoagulant as blood-based biomarker of breast cancer","volume":"22","author":"Haghbin","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1155\/2013\/715472","article-title":"Levels of circulating microparticles in lung cancer patients and possible prognostic value","volume":"35","author":"Tseng","year":"2013","journal-title":"Dis. Markers"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/IJGM.S236166","article-title":"Platelet-derived microparticles are an important biomarker in patients with cancer-associated thrombosis","volume":"12","author":"Yamanaka","year":"2019","journal-title":"Int. J. Gen. Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Liu, T., Wang, J., Li, T., Cui, P., Hou, B., Zhuang, C., Wei, G., Zhang, S., Li, H., and Hu, Y. (2021). Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08628-4"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/j.seminoncol.2014.04.010","article-title":"Involvement of platelet-derived microparticles in tumor progression and thrombosis","volume":"41","author":"Mezouar","year":"2014","journal-title":"Semin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2141.2003.04773.x","article-title":"Platelet microparticles induce angiogenesis in vitro","volume":"124","author":"Kim","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cardiores.2005.04.007","article-title":"Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization","volume":"67","author":"Brill","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mrrev.2011.05.002","article-title":"Initial steps of metastasis: Cell invasion and endothelial transmigration","volume":"728","author":"Krupitz","year":"2011","journal-title":"Mutat. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"dmm033100","DOI":"10.1242\/dmm.033100","article-title":"Metastasis in context: Modeling the tumor microenvironment with cancer-on-a-chip approaches","volume":"11","author":"Sleeboom","year":"2018","journal-title":"Dis. Model Mech."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/ijc.20657","article-title":"Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer","volume":"113","author":"Wysoczynski","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2016.01.006","article-title":"Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences","volume":"139","author":"Mezouar","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"665534","DOI":"10.3389\/fonc.2021.665534","article-title":"Platelet-cancer interplay: Molecular mechanisms and new therapeutic avenues","volume":"11","author":"Braun","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Metharom, P., Falasca, M., and Berndt, M.C. (2019). The history of Armand Trousseau and cancer-associated thrombosis. Cancers, 11.","DOI":"10.3390\/cancers11020158"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2016.06.033","article-title":"Epidemiology of venous thromboembolism in the Framingham Heart Study","volume":"145","author":"Puurunen","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fcvm.2017.00067","article-title":"Cancer and thrombotic risk: The platelet paradigm","volume":"4","author":"Lee","year":"2017","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"180119","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: The when, how and why","volume":"28","author":"Fernandes","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40248-015-0021-4","article-title":"Venous thromboembolism and lung cancer: A review","volume":"10","author":"Vitale","year":"2015","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/JTO.0b013e31811ea275","article-title":"High risk of deep vein thrombosis in patients with non-small cell lung cancer: A cohort study of 493 patients","volume":"2","author":"Tagalakis","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1538-7836.2008.02908.x","article-title":"The incidence of venous thromboembolism among patients with primary lung cancer","volume":"6","author":"Chew","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2012.09.007","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer","volume":"78","author":"Connolly","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-0033-1344341","article-title":"H\u00e4ufigkeit thromboembolischer Komplikationen bei Patienten mit Lungenkarzinom [Frequency of thromboembolic complications in patients with lung cancer]","volume":"67","author":"Crolow","year":"2013","journal-title":"Pneumologie"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1378\/chest.13-2379","article-title":"Prevalence and associations of VTE in patients with newly diagnosed lung cancer","volume":"146","author":"Zhang","year":"2014","journal-title":"Chest"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"125706","DOI":"10.1155\/2014\/125706","article-title":"The incidence and predictors of thromboembolic events in patients with lung cancer","volume":"2014","author":"Kadlec","year":"2014","journal-title":"Sci. World J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/bjc.2016.364","article-title":"Risk of venous thromboembolism in people with lung cancer: A cohort study using linked UK healthcare data","volume":"116","author":"Walker","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1634\/theoncologist.2017-0205","article-title":"Predictors of venous thromboembolism and early mortality in lung cancer: Results from a Global Prospective Study (CANTARISK)","volume":"23","author":"Kuderer","year":"2018","journal-title":"Oncologist"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10732748221145074","DOI":"10.1177\/10732748221145074","article-title":"Risk factors and impact on outcomes of lung cancer patients concurrent with deep vein thrombosis","volume":"29","author":"Jin","year":"2022","journal-title":"Cancer Control"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2015.01.006","article-title":"Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis","volume":"88","author":"Kravchenko","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/CIRCULATIONAHA.118.035516","article-title":"Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment","volume":"138","author":"Handy","year":"2018","journal-title":"Circulation"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Batra, A., Sheka, D., Kong, S., and Cheung, W.Y. (2020). Impact of pre-existing cardiovascular disease in patients with lung cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07487-9"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"950971","DOI":"10.3389\/fonc.2022.950971","article-title":"Cardiovascular disease and risk of lung cancer incidence and mortality: A nationwide matched cohort study","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zaborowska-Szmit, M., Szmit, S., Olszyna-Serementa, M., Badurak, P., Zadja, M., Janowicz-Zebrowska, A., Pi\u00f3rek, A., Knetki-Wr\u00f3blewska, M., Ja\u015bkiewicz, P., and Pluza\u0144ski, A. (2023). Beta blockers with statins may decrease all-cause mortality in patients with cardiovascular diseases and locally advanced unresectable non-small-cell lung cancer after chemoradiotherapy. Cancers, 15.","DOI":"10.3390\/cancers15041277"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Palacios-Acedo, A.L., Langiu, M., Crescence, L., M\u00e8ge, D., Dubois, C., and Panicot-Dubois, L. (2022). Platelet and cancer-cell interactions modulate cancer-associated thrombosis risk in different cancer types. Cancers, 14.","DOI":"10.3390\/cancers14030730"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5482\/HAMO-13-10-0054","article-title":"Platelets in cancer and thrombosis","volume":"34","author":"Riedl","year":"2014","journal-title":"Hamostaseologie"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Plantureux, L., M\u00e8ge, D., Crescence, L., Dignat-George, F., Dubois, C., and Panicot-Dubois, L. (2018). Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers, 10.","DOI":"10.3390\/cancers10110441"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.biopha.2018.09.177","article-title":"The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer","volume":"108","author":"Masjedi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"ref_118","unstructured":"Kim, H.J., Dong, J.F., Song, Y., Jung, H.I., and Song, J. (2023). The Effect of IL-6-Primed Platelets on ADAMTS13-Mediated Clearance of Platelet-Bearing ULVWF and Its Mechanism. Res. Sq., preprint."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2183\/pjab.84.189","article-title":"Platelet aggregation in the formation of tumor metastasis","volume":"84","author":"Tsuruo","year":"2008","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"909767","DOI":"10.3389\/fonc.2022.909767","article-title":"Tumor cell-induced platelet aggregation as an emerging therapeutic target for cancer therapy","volume":"12","author":"Strasenburg","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fcell.2016.00147","article-title":"Cancer and thrombosis: The platelet perspective","volume":"4","author":"Meikle","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/j.1538-7836.2008.03156.x","article-title":"Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer","volume":"6","author":"Khorana","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_123","first-page":"123","article-title":"Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis","volume":"20","author":"Tran","year":"2008","journal-title":"Oncol. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1538-7836.2006.02301.x","article-title":"Microvesicle-associated tissue factor and Trousseau\u2019s syndrome","volume":"5","author":"Bharwani","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/thx.2004.031492","article-title":"Trousseau\u2019s syndrome associated with tissue factor produced by pulmonary adenocarcinoma","volume":"61","author":"Sato","year":"2006","journal-title":"Thorax"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.7150\/jca.37321","article-title":"Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer","volume":"11","author":"Xia","year":"2020","journal-title":"J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"8983763","DOI":"10.1155\/2017\/8983763","article-title":"Tissue factor pathway inhibitor-1 is a valuable marker for the prediction of deep venous thrombosis and tumor metastasis in patients with lung cancer","volume":"2017","author":"Fei","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.thromres.2014.07.006","article-title":"Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients","volume":"134","author":"Nadir","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/bloodadvances.2020003149","article-title":"Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer","volume":"5","author":"Hisada","year":"2021","journal-title":"Blood Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10555-019-09806-4","article-title":"The plasminogen activator inhibitor-1 paradox in cancer: A mechanistic understanding","volume":"38","author":"Kubala","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1038\/s41598-017-04324-1","article-title":"Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation","volume":"7","author":"Miyata","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2019001388","article-title":"Platelets and cancer-associated thrombosis: Focusing on the platelet activation receptor CLEC-2 and podoplanin","volume":"134","year":"2019","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"807600","DOI":"10.3389\/fimmu.2021.807600","article-title":"Platelet CLEC2-podoplanin axis as a promising target for oral cancer treatment","volume":"12","author":"Hwang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2018015966","article-title":"Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells","volume":"3","author":"Costa","year":"2019","journal-title":"Blood Adv."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Xu, M., Wang, X., Pan, Y., Zhao, X., Yan, B., Ruan, C., Xia, L., and Zhao, Y. (2019). Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5808-9"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jth.13604","article-title":"C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice","volume":"15","author":"Shirai","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2011","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Frere, C., Lejeune, M., Kubicek, P., Faille, D., Marjanovic, Z., and Groupe Francophone Thrombose et Cancer (2019). Antiplatelet agents for cancer prevention: Current evidences and continuing controversies. Cancers, 11.","DOI":"10.3390\/cancers11111639"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/blood.2019003977","article-title":"Aspirin and antiplatelet treatments in cancer","volume":"137","author":"Tao","year":"2021","journal-title":"Blood"},{"key":"ref_142","unstructured":"Alexander, W. (2023, June 07). Unprecedented Drop Seen in Early Colorectal Cancer Cases Due to Aspirin Use. Conference Coverage. MDedge Internal Medicine. Available online: https:\/\/www.mdedge.com\/internalmedicine\/article\/263262\/oncology\/unprecedented-drop-seen-early-colorectal-cancer-cases-due."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1074248417708617","article-title":"Role for thrombin receptor antagonism with vorapaxar in secondary prevention of atherothrombotic events: From bench to bedside","volume":"23","author":"Moon","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bcp.12795","article-title":"Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma","volume":"81","author":"Bergmann","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Denslow, A., \u015awitalska, M., Jarosz, J., Papiernik, D., Porshneva, K., Nowak, M., and Wietrzyk, J. (2017). Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188740"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"202","DOI":"10.21037\/apm-20-2229","article-title":"Serum IL-6 as a vital predictor of severe lung cancer","volume":"10","author":"An","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e000678","DOI":"10.1136\/jitc-2020-000678","article-title":"Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC","volume":"8","author":"Keegan","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jth.14808","article-title":"Antisense oligonucleotide targeting of thrombopoietin represents a novel platelet depletion method to assess the immunomodulatory role of platelets","volume":"18","author":"Barrett","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/bloodadvances.2022007863","article-title":"Targeting platelet GPVI with glenzocimab: A novel mechanism for inhibition","volume":"7","author":"Billiald","year":"2023","journal-title":"Blood Adv."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Karolczak, K., and Watala, C. (2021). Blood platelets as an important but underrated circulating source of TGF\u03b2. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094492"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1061394","DOI":"10.3389\/fimmu.2022.1061394","article-title":"TGF-\u03b2: A novel predictor and target for anti-PD-1\/PD-L1 therapy","volume":"13","author":"Yi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Ramundo, V., Palazzo, M.L., and Aldieri, E. (2023). TGF-\u03b2 as predictive marker and pharmacological target in lung cancer approach. Cancers, 15.","DOI":"10.3390\/cancers15082295"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0169-5002(96)00611-3","article-title":"Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: A possible tumor marker","volume":"16","author":"Kong","year":"1996","journal-title":"Lung Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/5584_2015_115","article-title":"Clinical Significance of HMGB-1 and TGF-\u03b2 Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer","volume":"Volume 852","author":"Pokorski","year":"2015","journal-title":"Respiratory Carcinogenesis"},{"key":"ref_155","unstructured":"NIH\u2014U.S. National Library of Medicine (2023, June 07). SABR-ATAC: A Trial of TGF-Beta Inhibition and Stereotactic Ablative Radiotherapy for Early STAGE Non-Small Cell Lung Cancer. NTC 02581787. Last Update: April 2023, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02581787."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/oncolo\/oyac253","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with non-small cell lung cancer resistant or refractory to immune checkpoint inhibitors","volume":"28","author":"Barlesi","year":"2023","journal-title":"Oncologist"},{"key":"ref_157","unstructured":"NIH\u2014U.S. National Library of Medicine (2023, June 13). M7824 versus Pembrolizumab as a First-Line (1L) Treatment in Participants with Programmed Death-Ligand 1 (PD-L1) Expressing Advanced Non-Small Cell Lung Cancer (NSCLC). NCT03631706. Last Update: 6 May 2023, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03631706."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/11927\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:18:50Z","timestamp":1760127530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/11927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":157,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241511927"],"URL":"https:\/\/doi.org\/10.3390\/ijms241511927","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]}}}